{
  "docId": "019dd923-622c-750b-8b9a-21918ac10c17",
  "docSlug": "f3db2294dcf9",
  "documentTitle": "Harmony Biosciences (HRMY)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2023-03-28 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 110,
  "pageCount": 366,
  "prevPage": 109,
  "nextPage": 111,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a 'before-after' or 'comparison' structure to highlight the exclusion criteria in two different trial papers.",
  "elementsJson": [
    "paragraph",
    "screenshot"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-21918ac10c17/110",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17#slide-110",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "No cardiovascular exclusion criteria is listed in the pilot study, and we believe that the decision to then exclude such patients is an admission of the cardiotoxicity signal in the pilot study – as well as a reckless attempt to cherry-pick patients not reflective of a real-world clinical setting.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64d0-7099-9cd2-016499654a55",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.42,
        "x": 0.51,
        "y": 0.51
      },
      "kind": "paragraph",
      "text": "Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial. Exclusion criteria were participation in another trial... a serious cardiovascular disorder, severe hepatic or renal abnormalities...",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "593368dc-36d1-417e-8c40-279063e24932",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.42,
        "x": 0.07,
        "y": 0.51
      },
      "kind": "paragraph",
      "text": "Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Exclusion criteria were the use of any investigational drug... a serious cardiovascular disorder, hepatic or renal abnormalities, or a psychiatric disorder.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "64915c1f-2d6c-44c5-8c63-6d2a6b976913",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.42,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "paragraph",
      "text": "In addition to slashing the dose in later studies, Bioprojet’s pivotal phase 3 trials for pitolisant – now known as Harmony 1 and Harmony CTP - made another revealing decision: excluding patients with “serious cardiovascular disorder,” which is never defined.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e64fdde8-8cfe-4b4b-8e87-1d3a5eb8c889",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.75,
        "x": 0.07,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: https://pubmed.ncbi.nlm.nih.gov/24107292/; https://pubmed.ncbi.nlm.nih.gov/28129985/; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6802569/pdf/zsz174.pdf",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8635eec1-368a-4053-b6bd-772e084bfc80",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.38,
        "x": 0.51,
        "y": 0.46
      },
      "kind": "title",
      "text": "Harmony CTP pivotal phase 3 trial paper",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "83b99879-732c-4fc9-99b4-79345b253456",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.38,
        "x": 0.07,
        "y": 0.46
      },
      "kind": "title",
      "text": "Harmony 1 pivotal phase 3 trial paper",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fff5740e-26bf-4305-806d-b78fcf61af20",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "5e4dd9b0-0a95-46c8-a97c-4e491cf87ddd",
      "evidence": "The slide explicitly claims the exclusion criteria are a 'reckless attempt to cherry-pick patients' and an 'admission of the cardiotoxicity signal'.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}